The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma
Abstract
Metastatic renal cell carcinoma (RCC) associates with overproduction of vascular endothelial growth factor (VEGF) due to the mutation/inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. Herein we demonstrate that implantation of human RCC tumor cells into athymic nude mice promotes the appearance of VEGF receptor 1 (VEGFR1)/CD11b double-positive myeloid cells in peripheral blood. Avastin-mediated VEGF neutralization was capable of significantly reducing the numbers of circulating VEGFR1+ myeloid cells. Conversely, up-regulation of VEGFR1 by myeloid cells could also be achieved in vitro by coculturing bone marrow cells with RCC-conditioned medium or by short-term exposure of naive myeloid cells to oxidative stress. Treatment of myeloid cells with H2O2, lipid peroxidation product 4-hydroxy-2(E)-nonenal, or an inhibitor of thioredoxin reductase all resulted in increased expression of VEGFR1. Furthermore, after exposure to oxidative stress, myeloid cells acquire immunosuppressive features and become capable of inhibiting T cell proliferation. Data suggest that tumor-induced oxidative stress may promote both VEGFR1 up-regulation and immunosuppressive function in bone marrow-derived myeloid cells. Analysis of tumor tissue and peripheral blood from patients with metastatic RCC revealed that VEGFR1+ cells can be also found in cancer patients. Restoration of immunocompetence in metastatic RCC patients by pharmacological elimination of VEGFR1+ cells may have a significant impact on the therapeutic efficacy of cancer vaccines or other immune-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
VEGF-Induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells
Grunewald, M., Avraham, I., Dor, Y., Bachar-Lustig, E., Itin, A., Yung, S., Chimenti, S., Landsman, L., Abramovitch, R., & Keshet, E. (2006) · Cell · doi:10.1016/j.cell.2005.10.036 · Cited by 1,126
Dannull, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25947 · Cited by 989
Schmielau, J., & Finn, O. J. (2001) · PubMed · Cited by 867
Molecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Zea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 851
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
Self-citationTumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes
Gerber, H.-P., Condorelli, F., Park, J., & Ferrara, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23659 · Cited by 794
Hattori, K., Heissig, B., Wu, Y., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Bohlen, P., Witte, L., et al. (2002) · Nature Medicine · doi:10.1038/nm740 · Cited by 633
The thioredoxin system in cancer
Arnér, E. S. J., & Holmgren, A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.10.009 · Cited by 589
Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
Kusmartsev, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4880 · Cited by 445
Self-citationKusmartsev, S. A., Li, Y., & Chen, S.-H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.2.779 · Cited by 355
Self-citationCancer immunotherapy with mRNA‐transfected dendritic cells
Gilboa, E., & Vieweg, J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00139.x · Cited by 316
Self-citationTatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Mueller-Berghaus, J., Kirkwood, J. M., Kwok, W. W., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012142 · Cited by 314
Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells
Kusmartsev, S., Nagaraj, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4583 · Cited by 310
Self-citationBussolati, B., Dunk, C., Grohman, M., Kontos, C. D., Mason, J., & Ahmed, A. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61775-0 · Cited by 284
Predicting benefit from anti-angiogenic agents in malignancy
Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228
Kusmartsev, S., & Gabrilovich, D. I. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9002-6 · Cited by 183
Self-citationThe von Hippel–Lindau Protein, Vascular Endothelial Growth Factor, and Kidney Cancer
George, D. J., & Kaelin, W. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmp030061 · Cited by 165
Inhibition of Thioredoxin and Thioredoxin Reductase by 4-Hydroxy-2-nonenal in Vitro and in Vivo
Fang, J., & Holmgren, A. (2006) · Journal of the American Chemical Society · doi:10.1021/ja057358l · Cited by 164
Saio, M., Radoja, S., Marino, M., & Frey, A. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.5583 · Cited by 157
Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens
Amato, R. J. (2004) · Annals of Oncology · doi:10.1093/annonc/mdi002 · Cited by 120
Pickle, L., Hao, Y.-P., Jemal, A., Zou, Z.-H., Tiwari, R. C., Ward, E. M., Hachey, M., Howe, H., & Feuer, E. (2007) · Ca · doi:10.3322/canjclin.57.1.30 · Cited by 116
Ecstasy danger hits the headlines
Jones, R. (2002) · Nature reviews. Neuroscience · doi:10.1038/nrn974 · Cited by 103
Reversal of Tumor-Mediated Immunosuppression
Vieweg, J., Su, Z. Z., Dahm, P., & Kusmartsev, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1924 · Cited by 93
Self-citationMagnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non–Hodgkin's Lymphoma
Ruan, J., Hyjek, E. M., Kermani, P., Christos, P. J., Hooper, A. T., Coleman, M., Hempstead, B. L., Leonard, J. P., Chadburn, A., & Rafii, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1204 · Cited by 88
EGF and PDGF Receptor Tyrosine Kinases as Therapeutic Targets for Chronic Lung Diseases
Ingram, J. T., & Bonner, J. C. (2006) · Current Molecular Medicine · doi:10.2174/156652406777435426 · Cited by 86
An SDF-1 Trap for Myeloid Cells Stimulates Angiogenesis
de Almodóvar, C. R., Luttun, A., & Carmeliet, P. (2006) · Cell · doi:10.1016/j.cell.2005.12.023 · Cited by 73
Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
Martínez-Sánchez, G., & Giuliani, A. (2007) · PubMed · Cited by 45
Innovations and Challenges in Renal Cancer
Atkins, M. B., Avigan, D., Bukowski, R. M., Childs, R. W., Dutcher, J. P., Eisen, T. G., Figlin, R. A., Finke, J. H., Flanigan, R. C., George, D. J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040720 · Cited by 41
Mechanisms of Immune Dysfunction in Renal Cell Carcinoma
Derweesh, I., Tannenbaum, C. S., Rayman, P. A., & Finke, J. H. (2003) · Cancer treatment and research · doi:10.1007/978-1-4615-0451-1_2 · Cited by 19
Cited by
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Identification of ROS Using Oxidized DCFDA and Flow-Cytometry
Eruslanov, E., & Kusmartsev, S. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-411-1_4 · Cited by 1,321
Self-citation
Metadata
- Authors
- Kusmartsev, S., Eruslanov, E., Kübler, H., Tseng, T., Sakai, Y., Su, Z., Kaliberov, S., Heiser, A., Rosser, C., Dahm, P., Siemann, D., & Vieweg, J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-07-01
- Volume
- 181
- Issue
- 1
- Pages
- 346-353
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1838939739
- Cited by
- 276
- References
- 38
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.